news
Sanofi and GSK to collaborate on COVID-19 vaccine development
Sanofi will provide its S protein antigen and GSK will contribute its adjuvant technology in a partnership to develop a COVID-19 vaccine.
List view / Grid view
GlaxoSmithKline (GSK)
Filter the results
article
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
news
FDA approves Advil Dual Action for over-the-counter pain relief
Advil Dual Action is the first FDA-approved an over-the-counter ibuprofen and acetaminophen combination, backed up with data from several clinical trials proving its efficacy.
news
Global collaboration formed to develop novel treatment regimens for TB
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) was devised to create transformative regimens for TB treatment, irrespective of drug resistance status.
article
Five of the most recent developments in anti-cancer therapeutics
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
news
FDA accepts Zejula sNDA application as a maintenance treatment for ovarian cancer
The developers of Zejula (niraparib) have announced the FDA will assess the sNDA application under the Real-Time Oncology Review (RTOR) pilot programme.
news
COVID-19 update: therapeutic and regulatory developments
European Pharmaceutical Review rounds up the latest news surrounding COVID-19, including a vaccine moving to clinical trials and the FDA's update on Chinese import inspections.
news
Voltaren approved for arthritis pain over-the-counter in the US
Voltaren Arthritis Pain has been approved by the FDA as an over-the-counter product for the temporary relief of arthritis pain.
article
Does the antibacterial pipeline sufficiently target WHO priority pathogens?
A WHO review has concluded that while innovative therapies have been developed for TB and C. diff, other priority pathogens are likely to develop resistance to future therapies.
news
EU court rules GSK committed ‘pay-for-delay’ in paroxetine case
The Competition and Markets Authority (CMA) announced the EU Court of Justice agreed that GSK had paid to delay other competitors entering the UK paroxetine generics market.
news
GSK halts Excedrin production due to manufacturing inconsistencies
GlaxoSmithKline has announced that it will not be manufacturing or distributing some of its Excedrin products after inconsistencies in ingredient transfer and weight.
article
The biggest pharma merger and acquisition deals of 2019
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
article
Intellectual property, divestments, fragmentation and the future: M&A in life sciences
Mergers and acquisitions in any market can define the landscape for its players. In this article, Emma Danks of Taylor Wessing reflects on recent M&A activity in the biopharmaceutical industry, highlighting influencing trends and what this might mean for the future.
news
Candidate vaccine shows sustained protection against pulmonary TB
A candidate TB vaccine’s efficacy level and acceptable safety profile have been confirmed in a three-year clinical trial.
article
Developing new antibiotics – essential research should not be a question of money
Why has the pharma industry and its talents lost interest in developing new antibiotics?